EUVIMEDEUVIMED entdecken
Crossref

Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies

Tejashree Waghule, K Laxmi Swetha, Aniruddha Roy, Ranendra Narayan Saha, Gautam Singhvi

European Journal of Pharmaceutics and Biopharmaceutics · 2023-05 · 186 · 18-29

DOI: 10.1016/j.ejpb.2023.03.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023-05. Verfasst von Tejashree Waghule und 4 weiteren Autor:innen. Beteiligte Einrichtung: Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, India. Hauptthemen laut MEDLINE: Temozolomide, Liposomes. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Temozolomide (TMZ) is one of the best choices for treating glioblastoma. However, due to the short plasma half-life, only 20-30 % brain bioavailability can be achieved using traditional formulations. In the present study, PEGylated liposomes and lyotropic liquid crystals (LLCs) were developed and investigated to prolong the plasma circulation time of TMZ. Industrially feasible membrane extrusion and modified hot melt emulsification techniques were utilized during the formulation. Liposomes and LLCs in the particle size range of 80-120 nm were obtained with up to 50 % entrapment efficiency. The nanocarriers were found to show a prolonged release of up to 72 h. The cytotoxicity studies in glioblastoma cell lines revealed a ∼1.6-fold increased cytotoxicity compared to free TMZ. PEGylated liposomes and PEGylated LLCs were found to show a 3.47 and 3.18-fold less cell uptake in macrophage cell lines than uncoated liposomes and LLCs, respectively. A 1.25 and 2-fold increase in the plasma t1/2 was observed with PEGylated liposomes and PEGylated LLCs, respectively, compared to the TMZ when administered intravenously. Extending plasma circulation time of TMZ led to significant increase in brain bioavailability. Overall, the observed improved pharmacokinetics and biodistribution of TMZ revealed the potential of these PEGylated nanocarriers in the efficient treatment of glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideLiposomesLiquid CrystalsPolyethylene GlycolsHumansHalf-LifeGlioblastomaBrain NeoplasmsTissue DistributionBlood-Brain BarrierNanoparticle Drug Delivery SystemAntineoplastic Agents, AlkylatingMaleAnimalsRats

Stichwörter der Autor:innen

CytotoxicityGlioblastomaLiposomesLiquid crystalsPEGylationTemozolomide

Substanzen

TemozolomidePolyethylene GlycolsLiposomesNanoparticle Drug Delivery SystemAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, India.
  • Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, India. Electronic address: gautam.singhvi@pilani.bits-pilani.ac.in.

Zitieren

APA

Waghule, T., Laxmi Swetha, K., Roy, A., Narayan Saha, R., & Singhvi, G. (2023). Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies. European Journal of Pharmaceutics and Biopharmaceutics, 186, 18-29. https://doi.org/10.1016/j.ejpb.2023.03.004

Vancouver

Waghule T, Laxmi Swetha K, Roy A, Narayan Saha R, Singhvi G. Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies. European Journal of Pharmaceutics and Biopharmaceutics. 2023;186:18-29. doi:10.1016/j.ejpb.2023.03.004

BibTeX
@article{Waghule2023,
  author = {Waghule, Tejashree and Laxmi Swetha, K and Roy, Aniruddha and Narayan Saha, Ranendra and Singhvi, Gautam},
  title = {Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2023},
  volume = {186},
  pages = {18--29},
  doi = {10.1016/j.ejpb.2023.03.004}
}
Kostenlos starten →